These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 24813654)
21. [Pharmacokinetics of controlled-release oxycodone in patients with cancer pain]. Nakamura K; Kokubun H; Komatsu T; Matoba M; Hoka S; Yago K Gan To Kagaku Ryoho; 2007 Sep; 34(9):1449-53. PubMed ID: 17876144 [TBL] [Abstract][Full Text] [Related]
22. In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics. Boström E; Simonsson US; Hammarlund-Udenaes M Drug Metab Dispos; 2006 Sep; 34(9):1624-31. PubMed ID: 16763013 [TBL] [Abstract][Full Text] [Related]
23. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans. Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605 [TBL] [Abstract][Full Text] [Related]
24. A single-dose, 3-way crossover pharmacokinetic comparison between immediate-release oxycodone hydrochloride with aversion technology (IRO-A, Oxecta), IRO-a with Niacin, and Oxycodone Hydrochloride (Roxicodone) in healthy adults under fasting conditions. Leibowitz MT; Zamora CA; Brzeczko AW; Stark JG Am J Ther; 2014; 21(2):99-105. PubMed ID: 22357166 [TBL] [Abstract][Full Text] [Related]
25. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone. Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663 [TBL] [Abstract][Full Text] [Related]
26. The use of liquid chromatography/mass spectrometry for quantitative analysis of oxycodone, oxymorphone and noroxycodone in Ringer solution, rat plasma and rat brain tissue. Boström E; Jansson B; Hammarlund-Udenaes M; Simonsson US Rapid Commun Mass Spectrom; 2004; 18(21):2565-76. PubMed ID: 15468158 [TBL] [Abstract][Full Text] [Related]
27. Effect of pH on sublingual absorption of oxycodone hydrochloride. Al-Ghananeem AM; Malkawi AH; Crooks PA AAPS PharmSciTech; 2006 Mar; 7(1):E23. PubMed ID: 16584154 [TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of oxycodone in children 6 months to 7 years old. El-Tahtawy A; Kokki H; Reidenberg BE J Clin Pharmacol; 2006 Apr; 46(4):433-42. PubMed ID: 16554451 [TBL] [Abstract][Full Text] [Related]
29. Oxycodone recycling: a novel hypothesis of opioid tolerance development in humans. Linares OA; Fudin J; Schiesser WE; Linares AD; Boston RC Med Hypotheses; 2014 Sep; 83(3):326-31. PubMed ID: 24986643 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Tallgren M; Olkkola KT; Seppälä T; Höckerstedt K; Lindgren L Clin Pharmacol Ther; 1997 Jun; 61(6):655-61. PubMed ID: 9209248 [TBL] [Abstract][Full Text] [Related]
31. Maturation of oxycodone pharmacokinetics in neonates and infants: Oxycodone and its metabolites in plasma and urine. Kokki M; Heikkinen M; Välitalo P; Hautajärvi H; Hokkanen J; Pitkänen H; Sankilampi U; Ranta VP; Kokki H Br J Clin Pharmacol; 2017 Apr; 83(4):791-800. PubMed ID: 27780305 [TBL] [Abstract][Full Text] [Related]
32. Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes. Huang L; Edwards SR; Smith MT Pharm Res; 2005 Sep; 22(9):1489-98. PubMed ID: 16132361 [TBL] [Abstract][Full Text] [Related]
33. Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics. Bergstrand M; Söderlind E; Weitschies W; Karlsson MO Clin Pharmacol Ther; 2009 Jul; 86(1):77-83. PubMed ID: 19387437 [TBL] [Abstract][Full Text] [Related]
34. Cancer cachexia raises the plasma concentration of oxymorphone through the reduction of CYP3A but not CYP2D6 in oxycodone-treated patients. Naito T; Tashiro M; Ishida T; Ohnishi K; Kawakami J J Clin Pharmacol; 2013 Aug; 53(8):812-8. PubMed ID: 23733622 [TBL] [Abstract][Full Text] [Related]
35. Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers. Smith K; Hopp M; Mundin G; Bond S; Bailey P; Woodward J; Palaniappan K; Church A; Limb M; Connor A Expert Opin Investig Drugs; 2011 Apr; 20(4):427-39. PubMed ID: 21395483 [TBL] [Abstract][Full Text] [Related]
36. Urine testing for norcodeine, norhydrocodone, and noroxycodone facilitates interpretation and reduces false negatives. Cone EJ; Zichterman A; Heltsley R; Black DL; Cawthon B; Robert T; Moser F; Caplan YH Forensic Sci Int; 2010 May; 198(1-3):58-61. PubMed ID: 20036472 [TBL] [Abstract][Full Text] [Related]
37. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Pöyhiä R; Seppälä T; Olkkola KT; Kalso E Br J Clin Pharmacol; 1992 Jun; 33(6):617-21. PubMed ID: 1389934 [TBL] [Abstract][Full Text] [Related]
38. Tentative identification of novel oxycodone metabolites in human urine. Moore KA; Ramcharitar V; Levine B; Fowler D J Anal Toxicol; 2003 Sep; 27(6):346-52. PubMed ID: 14516487 [TBL] [Abstract][Full Text] [Related]
39. Normal-release and controlled-release oxycodone: pharmacokinetics, pharmacodynamics, and controversy. Davis MP; Varga J; Dickerson D; Walsh D; LeGrand SB; Lagman R Support Care Cancer; 2003 Feb; 11(2):84-92. PubMed ID: 12560936 [TBL] [Abstract][Full Text] [Related]